Physician profile
George A Eyrich
NPI 1962493171
$3,478.98
in general payments reported to CMS, 2019-2025
26 companies · $219 in 2025
The $219 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $569 · 2020: $596 · 2021: $761 · 2022: $725 · 2023: $334 · 2024: $274 · 2025: $219.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $828.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $827.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $913.83 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $732.98 | 2019-2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $260.99 | 2020-2024 | Lifevest |
| Amgen INC. | $205.86 | 2019-2021 | |
| Pfizer INC. | $156.26 | 2019-2025 | |
| Cardiovascular Systems INC. | $140.56 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $137.53 | 2023-2025 | Camzyos, Eliquis |
| Ge Healthcare | $136.12 | 2024 | |
| Chiesi USA, INC. | $123.55 | 2020-2022 | |
| Astrazeneca Pharmaceuticals LP | $122.73 | 2019-2022 | |
| Medtronic, INC. | $84.82 | 2022-2023 | Onyx Frontier |
| Alnylam Pharmaceuticals INC. | $71.73 | 2022 | |
| Sanofi-Aventis U.S. LLC | $65.23 | 2022-2023 | |
| Esperion Therapeutics, INC. | $61.10 | 2020-2021 | |
| Philips North America LLC | $49.76 | 2019-2024 | (P79) Azurion 7 B20 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Baxter Healthcare | $45.88 | 2023 | Hillrom - Carnation Ambulatory Monitor |
| Gilead Sciences, INC. | $34.85 | 2019 | |
| Merck Sharp & Dohme LLC | $26.86 | 2023-2024 | Verquvo |
| Atricure, INC. | $23.03 | 2023 | |
| Shockwave Medical, INC | $17.33 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.87 | 2025 | Jardiance |
| Arbor Pharmaceuticals, INC. | $12.17 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $11.41 | 2021 | |
| Acutus Medical, INC. | $10.94 | 2020 | |
| Osprey Medical INC | $10.00 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $9.59 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw George Eyrich listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.